• Martina Pericolini, Gabriel Miget, Claire Hentzen, Enrico Finazzi Agrò, Camille Chesnel, Philippe Lagnau, Rebecca Haddad, Matthieu Grasland, and Gerard Amarenco.
• Urology Department, Policlinico Tor Vergata, Università Degli Studi di Roma, Rome, Italy; GRC 001, GREEN Groupe de recherche clinique en neuro-urologie, Hôpital Tenon, Sorbonne Université, Paris, AP-HP, France. Electronic address: martinapericolini@gmail.com.
• Neuromodulation. 2022 Dec 1; 25 (8): 106510751065-1075.

IntroductionMultiple sclerosis (MS) is often associated with urological disorders, mainly urinary incontinence and retention, the management of which being necessary to improve patient's quality of life (QOL) and to reduce potential urological complications. Besides the classical treatments based mainly on anticholinergics and/or self-catheterization, several neuromodulation techniques have been tried in recent years to improve these urinary disorders. By this review, we aim at providing an overview of neuromodulation and electrostimulation approaches to manage urinary symptoms in MS patients.Materials And MethodsA literature search using MEDLINE was performed. Only papers in English, and describing the effects of neuromodulation in MS patients, were considered.ResultsA total of 18 studies met inclusion criteria and were reviewed. Of them, four related to sacral neuromodulation (SNM), seven to percutaneous tibial nerve stimulation (PTNS), six to spinal cord stimulation (SCS), and one to transcranial magnetic stimulation (TMS).DiscussionPTNS and SNM seem to be effective and safe therapeutic options for treating lower urinary tract symptoms in MS patients principally in case of overactive bladder (OAB) symptoms. Similarly, also SCS and TMS have been shown to be effective, despite the very limited number of patients and the small number of studies found in the literature. Interestingly, these techniques are effective even in patients who do not respond well to conservative therapies, such as anticholinergics. Furthermore, given their safety and efficacy, stimulations such as PTNS could be considered as a first-line treatment for OAB in MS patients, also considering that they are often preferred by patients to other commonly used treatments.Copyright © 2022 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.

20 keywords...

hide…